Abstract: The present invention is directed to unsaturated sphingosine compounds which are useful as therapeutic agents for the treatment of cancer and for the treatment of other diseases including diabetes and infection with intracellular bacteria. This invention is also directed to methods of using the compounds and pharmaceutical compositions comprising the compounds in treating these diseases.

Abstract: The present disclosure provides methods for assessing bactericidal antibodies in a biological sample by use of human fresh whole blood from a non-immune human as a reaction medium for the assay.

Abstract: Polypeptides that can elicit antibodies that bind to T-cell stimulating protein B (TspB) of N. meningitidis, and methods of use, are provided.

Abstract: The present invention relates to compositions and methods of their production and use, including use in increasing de-N-acetyl sialic acid antigen of a mammalian cell and methods that exploit the increase in deNAc sialic acid antigen on such cells.

Abstract: The present disclosure provides a dietary supplement that includes plant ferritin; and methods of use of such a supplement.

Abstract: In one aspect, the present invention provides isolated oxidation resistant mutant apoA-I polypeptides comprising an amino acid sequence substantially homologous to SEQ ID NO:4, the mutant apoA-I polypeptide comprising a combination of: (1) a conservative amino acid substitution at residue Tyr192; and (2) at least one conservative amino acid substitution at residue Met86, Met112, or Met148, wherein the mutant apoA-I polypeptide is resistant to modification by an oxidizing agent. In another aspect, the invention provides a method of promoting cholesterol efflux activity in a mammalian subject in need thereof, the method comprising the step of administering an effective amount of an oxidation resistant apoA-I agonist to the subject to promote cholesterol efflux.

Abstract: The present disclosure generally provides methods for assessing a subject's responsiveness to a statin therapy, and selection of a statin dose based upon such methods. The disclosure further provides methods for treating asthma by administering a statin therapy.

Abstract: The present invention provides a method of classifying an epitope displayed by a polypeptide; a method of determining the presence of an epitope on a polypeptide encoded by a test nucleotide sequence; and a method of generating a nucleotide sequence encoding a polypeptide that exhibits a selected epitope. The present invention provides antigenic polypeptides that display selected epitope(s); chimeric macromolecules comprising such polypeptides; and compositions comprising the antigenic polypeptides or chimeric macromolecules. The present invention further provides methods of inducing an immune response to a Chlamydia. The present invention further provides arrays of nucleic acids, arrays of polypeptides, and arrays of antibodies, which arrays are useful in identification and/or classification of a Chlamydia.

Abstract: Assays for detection of bactericidal anti-Neisserial antibodies using a factor H polypeptide having a human amino acid sequence that mediates binding to Neisserial factor H binding protein (fHBp) are provided, as well as non-human animal models of Neisserial infection.

Abstract: Polypeptides that can elicit antibodies that are bactericidal for different fHbp variant strains of N. meningitidis, and methods of use, are provided.

Abstract: The invention provides compositions and methods for delivery of a bioactive agent to an individual. Delivery vehicles are provided that include a bioactive agent in disc shaped particles that include one or more lipid binding polypeptides circumscribing the perimeter of a lipid bilayer in which the bioactive agent is localized. Chimeric lipid binding polypeptides are also provided and may be used to add additional functional properties to the delivery particles.

Abstract: A method of using Joule heating to regenerate nanowire based biosensors. The nanowire based biosensor contains various detection molecules, such as nucleic acids, bound to the surface of the nanowire. Binding of analyte nucleic acids to the detection molecules alters the electrical properties of the nanowire, producing a detectable signal. By passing a Joule heating effective amount of electrical current through the nanowire, the nanowire may be heated to a temperature sufficient to dissociate the bound analyte from the detection molecule, without damaging the detection molecules or the bond between the detection molecules and the nanowire surface. The Joule heated nanowires may thus be regenerated to an analyte-free “fresh” state and used for further sensing. In alternate embodiments, the specificity of the nanowire for a particular analyte may be modulated by using Joule heating to heat the nanowire to an intermediate temperature where some analytes bind and some do not.

Abstract: The present invention relates, in part, to methods and compositions for immunizing against infection by Chlamydia trachomatis. The methods and compositions rely, in part, on administering an immunogenic composition comprising one or more peptides derived from C. trachomatis major outer membrane protein (MOMP) to a subject to be immunized. In some embodiments, the compositions comprise a chimeric immunogens, expression vectors comprising the polynucleotides, and kits comprising the compositions are also provided.

Abstract: The invention features methods and compositions for diagnosis, including prognosis, of conditions associated with decreased arginine bioavailability (which can result from dysregulated arginine metabolism, e.g., due to increased arginase activity) by assessing in a sample from a subject the ratio of arginine to one or more, usually two or more, modulators of arginine bioavailability. In one embodiment, the ratio of arginine to (ornithine+citrulline) is assessed to aid in diagnosis.

Abstract: The invention provides a device, system and method that enables a microfluidic flow lysometer cell analyzer. Using a population of suspended living cells. cell surface molecule detection reagents, and cell cytoplasm (or nuclear) molecule detection reagents, this microfluidic cell analyzer can rapidly analyze a population of cells by running them on a one-at-a-time basis through small capillary channels. The cell's morphology or surface markers are analyzed, then the cells are lysed, and the molecules present in the cell's cytoplasm or nuclear material are analyzed. Cell morphology is then analyzed as the cell surface molecules are correlated with the molecules present in the same cell's cytoplasm or nucleic acids, and this correlated cell population data is then presented to a user for interpretation.

Abstract: The present invention provides methods of cryopreserving stem and progenitor cells in a mammalian placenta; and methods of obtaining fetal stem and progenitor cells from a cryopreserved mammalian placenta. Cells obtained by carrying out the methods can be used in a variety of therapeutic applications.

Abstract: Provided herein are compositions and methods for delivery of nucleic acids to individuals and to cells, including nucleic acid delivery particles that comprising a lipid-binding polypeptide, a lipid bilayer comprising one or more cationic lipids, and a nucleic acid.

Abstract: The invention provides compositions and methods for delivery of a bioactive agent to an individual. Delivery vehicles are provided that include a bioactive agent in disc shaped particles that include one or more lipid binding polypeptides circumscribing the perimeter of a lipid bilayer in which the bioactive agent is localized. Chimeric lipid binding polypeptides are also provided and may be used to add additional functional properties to the delivery particles.

Abstract: The present invention provides a synthetic LDL nanoparticle comprising a lipid moiety and a synthetic chimeric peptide so as to be capable of binding the LDL receptor. The synthetic LDL nanoparticle of the present invention is capable of incorporating and targeting therapeutics to cells expressing the LDL receptor for diseases associated with the expression of the LDL receptor such as central nervous system diseases. The invention further provides methods of using such synthetic LDL nanoparticles.

Abstract: A Comprehensive Integrated Testing Protocol (CITP) incorporates precise measurements of the dynamic and the static lung volumes and capacities at V30 for routine infant lung function testing. The static functional residual capacity (sFRC) in infants is measured after a short hyperventilation induces a post-hyperventilation apnea (PHA) that abolishes the infant's breathing strategies and creates a reliable volume landmark. A measurement of the sFRC is then obtained by inert gas washout; e.g., by measuring the volume of nitrogen expired after end-passive expiratory switching of the inspired gas from room air to 100% oxygen during the PHA. A true measurement of the total lung capacity (TLC) is obtained from the sum of (1) the passively exhaled gas volume from a Pao plateau of 30 cm H2O through a pneumotachometer (PNT) by integrating the flow signal to produce volume, which is the inspiratory capacity (IC), and (2) the sFRC.